Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 647

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 647
---
 interest                                                                                                                                                    2,509               421               150  
  Cash paid for tax, net of refunds                                                                                                          24(iii)                        3,587             3,728            18,891  
  Supplemental disclosure for non-cash activities                                                                                                                                                                      
  (Decrease)/increase in accrued capital expenditures                                                                                                                    ( 7,540)             5,713             9,618  
  Vesting of treasury shares for LTIP                                                                                                        18(ii)                        42,127            18,148            12,034  

The accompanying notes are an integral part of these consolidated financial statements.

F-9

Table of Contents

HUTCHMED (CHINA) LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Nature of Business

HUTCHMED (China) Limited (the “ Company”) and its subsidiaries (together the “ Group”) are principally engaged in researching, developing, manufacturing and marketing pharmaceutical products. The Group and its equity investee have research and development facilities and manufacturing plants in the People’s Republic of China (the “ PRC”) and sell their products mainly in the PRC, including Hong Kong and Macau. In addition, the Group has established international operations in the United States of America (the “ US”) and Europe (“ EU”).

The Company’s ordinary shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited and the AIM market of the London Stock Exchange, and its American depositary shares (“ ADS”) are traded on the Nasdaq Global Select Market.

Liquidity

As at December 31, 2024, the Group had accumulated losses of US$833,172,000primarily due to its spending in drug research and development activities. The Group regularly monitors current and expected liquidity requirements to ensure that it maintains sufficient cash balances and adequate credit facilities to meet its liquidity requirements in the short and long term. As at December 31, 2024, the Group had cash and cash equivalents of US$153,958,000, short-term investments of US$682,152,000and unutilized bank borrowing facilities of US$60,549,000. Short-term investments comprised of bank deposits maturing over three months. Dividend received from Shanghai Hutchison Pharmaceuticals Limited (“ SHPL”) for the years ended December 31, 2024, 2023 and 2022 were US$34,936,000, US$42,308,